Welcome to our dedicated page for McKesson news (Ticker: MCK), a resource for investors and traders seeking the latest updates and insights on McKesson stock.
McKesson Corporation (NYSE: MCK) is a diversified healthcare services and pharmaceutical distribution company that regularly issues news and updates relevant to investors, healthcare partners, and other stakeholders. The company describes itself as dedicated to advancing health outcomes for patients everywhere, partnering with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products, and services that support access to quality care.
The McKesson news feed typically features announcements about quarterly and annual financial results, earnings release dates, and related investor webcasts. These updates often include information about fiscal guidance, long-term financial targets, and commentary on strategic priorities and business outlook shared during events such as Investor Day.
In addition to earnings and guidance, McKesson’s news includes Board actions such as dividend declarations, reflecting decisions on returning capital to shareholders. The company also issues releases on organizational and segment reporting changes, including the introduction of its North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions segments, along with portfolio developments like planned separations or divestitures.
McKesson may also appear in third-party announcements highlighting distribution agreements and collaborations that illustrate its role in pharmaceutical distribution and healthcare services. Such items can show how McKesson supports access to therapies through its distribution networks and healthcare supply chain capabilities.
For readers tracking MCK news, this page provides a centralized view of financial announcements, strategic updates, capital allocation decisions, and partnership-related developments. Regularly reviewing these items can help investors and observers understand how McKesson communicates its performance, segment evolution, and strategic focus within the healthcare and wholesale trade landscape.
McKesson Corporation (NYSE: MCK) is hosting an Investor Day at 1:00 p.m. ET today to outline its strategy for sustainable growth. The event will cover progress in healthcare services and reaffirm commitments to expanding oncology and biopharma services. McKesson increased its fiscal 2022 Adjusted Earnings per Diluted Share guidance to $22.35-$22.95, boosted by the U.S. government's COVID-19 vaccine program. Additionally, a $4.0 billion share repurchase program was announced, highlighting a focus on shareholder value.
McKesson Corporation (NYSE: MCK) is set to host an Investor Day on December 8, 2021, from 1:00 PM to 4:00 PM ET in New York City. The event will include presentations by the leadership team, a live Q&A with CEO Brian Tyler and CFO Britt Vitalone, and discussions on the company’s progress towards sustainable growth and long-term financial outlook.
A video webcast will be available live and archived on McKesson's Investor Relations website.
Walgreens Boots Alliance (WBA) has announced its agreement to acquire the remaining 30% share of its joint venture with McKesson Corporation (MCK) in Germany, making WBA the sole owner of GEHE Pharma Handel and Alliance Healthcare Deutschland. This acquisition is part of McKesson's strategy to fully exit the European market. The transaction's financial terms were not disclosed and are subject to regulatory approval. This move aims to strengthen WBA's presence in the German pharmaceutical distribution market.
McKesson Corporation (NYSE: MCK) has released its fiscal 2022 second-quarter financial results. The earnings call is scheduled for November 1 at 4:30 PM ET, and results can be accessed on McKesson’s Investor Relations website. The company is recognized as a leader in healthcare supply chain management and has received accolades such as being named the "Most Admired Company" in its sector by FORTUNE. For further details, visit investor.mckesson.com/financials/quarterly-results.
McKesson Corporation (NYSE: MCK) has announced plans to sell its UK businesses to AURELIUS as part of its strategy to fully exit the European market. This includes the sale of entities like LloydsPharmacy and AAH Pharmaceuticals. The transaction is set to close in fiscal 2022, pending regulatory approvals. CEO Brian Tyler emphasized that this move allows for better long-term growth opportunities for the UK operations while enabling McKesson to focus on strategic investments outside Europe. This sale follows a previous agreement to divest businesses in several European countries.
The Board of Directors of McKesson Corporation (NYSE:MCK) has declared a regular dividend of 47 cents per share of common stock. This dividend will be payable on January 3, 2022, to stockholders of record as of December 1, 2021. This announcement highlights McKesson's commitment to returning value to its shareholders while maintaining its position as a leader in healthcare supply chain management and services.
Hercules Capital has appointed Pam Randhawa to its Board of Directors, effective November 1, 2021. With over 20 years in the healthcare and life sciences sectors, her background includes leadership positions at McKesson and her own firm, Empiriko Corporation. Randhawa's expertise is expected to enhance the board's capabilities as Hercules focuses on long-term growth and shareholder returns. CEO Scott Bluestein praised her contributions within the life sciences community, indicating her appointment is part of a strategy to bolster the company's leadership team.
AmerisourceBergen (ABC), Cardinal Health (CAH), and McKesson (MCK) have settled opioid-related claims with the Cherokee Nation for approximately $75 million over 6.5 years. This agreement resolves ongoing litigation and allows the companies to focus on safe medication delivery. The settlement is part of broader negotiations with federally recognized Native American tribes, despite the companies disputing the allegations against them. The firms emphasize their commitment to addressing the opioid epidemic's impact on communities.
McKesson Corporation (NYSE: MCK) is set to release its second quarter fiscal 2022 financial results on November 1, 2021, after market close. The earnings conference call will take place at 4:30 PM Eastern Time, which will be available via a live webcast on McKesson's Investor Relations website. Investors can access the earnings press release, financial tables, and slide presentation online following the conference.
McKesson Corporation (NYSE:MCK) announced the election of Dr. Richard H. Carmona as an independent director, effective Sept. 6, 2021. Dr. Carmona brings extensive healthcare experience, including his role as the 17th Surgeon General of the United States. He aims to improve public health access, reflecting McKesson's mission to enhance care across various settings. The board chair, Edward Mueller, expressed confidence in Dr. Carmona’s contributions to the company's future direction.